Evidence map›Paper›PMID 26659914›Full record

Trial reportHaematologica2016

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Edo Vellenga, Ellen Meijer, Shulamit Wittebol, Bea C Tanis, Petra B Cornelisse and 5 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Annemiek BroijlDepartment of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands a.broyl@erasmusmc.nl.
Marie-José KerstenDepartment of Hematology, Academic Medical Center (AMC), Amsterdam, the Netherlands.
Wendimagegn Ghidey AlemayehuHOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
Mark-David LevinDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Okke de WeerdtDepartment of Hematology, Antonius Hospital, Nieuwegein, the Netherlands.
Edo VellengaDepartment of Hematology, University Medical Center (UMCG), Groninge, the Netherlands.
Ellen MeijerDepartment of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
Shulamit WittebolDepartment of Hematology, Meander Medical Center, Amersfoort, the Netherlands.
Bea C TanisDepartment of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.
Petra B CornelisseHOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
Marian Stevens-KroefWorking group on Hemato-Oncologic Genome Diagnostics (WHGD), Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Gerard M J BosDepartment of Hematology, University Hospital, Maastricht, the Netherlands.
Pierre W WijermansDepartment of Hematology, HAGA Hospital, the Hague, the Netherlands.
Henk LokhorstDepartment of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDrug Administration ScheduleDrug Dosage CalculationsFemaleHumansLenalidomideLogistic ModelsMaleMaximum Tolerated DoseMiddle AgedMultiple MyelomaNeoplasms, Second PrimaryBortezomibDexamethasoneLenalidomideThalidomideescalated dosefirst relapsemultiple myelomaVRD

Identifiers

PMID26659914
PMCPMC5004394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.